Kornimate/medical-research-clean huggingface dataset:
efficacy of topical cannabidiol for eczema

Conditions: Chronic Pruritus; Eczema; Nummular Eczema; Atopic Dermatitis; Prurigo Nodularis

Summary: itching is a common symptom encountered in general medical practice. it can cause significant discomfort, disrupt sleep, and impair patients' quality of life. chronic pruritic skin conditions such as atopic dermatitis, nummular eczema, lichen simplex chronicus, and prurigo nodularis are frequently observed. the pathogenesis of these conditions remains incompletely understood, and effective long-term treatment options are limited. current therapies include topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, and systemic immunosuppressants. however, these treatments are often associated with adverse effects, and the diseases tend to follow a chronic, relapsing course. therefore, the investigators aim to investigate the efficacy and safety of topical cannabis extract in patients with chronic pruritic skin conditions.


Eligibility criteria:
inclusion criteria: 1. all participants must be aged 25 years or older. 2. patients must be diagnosed with eczema, including atopic dermatitis, nummular eczema, lichen simplex chronicus, or prurigo nodularis, with pruritus persisting for more than 6 weeks. 3. patients must be willing to refrain from using other topical products throughout the 4-week study period. 4. patients must provide written informed consent to participate in the study. exclusion criteria: 1. patients who have taken oral steroids, immunosuppressive drugs, or received phototherapy within the past 3 months. 2. patients with chronic kidney disease, liver cirrhosis, cancer, or thyroid disease. 3. pregnant or breastfeeding women, or women planning to become pregnant. 4. patients who develop erythematous itchy rash in response to an open patch test using cannabis extract products. 5. patients with a known allergy to cannabis-derived products, which may result from other ingredients and/or solvents used in the extraction process. 6. patients with severe or unstable cardio-pulmonary diseases (e.g., angina, peripheral vascular disease, cerebrovascular disease, or arrhythmia), or those at risk of cardiovascular disease. 7. patients with a history of psychosis, current active mood disorder, or anxiety disorder. 8. patients who are addicted to substances, including nicotine, or are heavy alcohol users. 9. patients using other medications, particularly opioids or sedatives such as benzodiazepines. 10. patients taking medications known to potentially interact with cannabis extracts, such as warfarin, fluoroquinolones, or dihydropyridine calcium channel blockers.
tx2® low profile taa endovascular graft

Conditions: Aortic Aneurysm; Penetrating Ulcer; Vascular Disease

Summary: the zenith® tx2® low profile taa endovascular graft study is a clinical trial approved by us fda to evaluate the safety and effectiveness of the zenith® tx2® low profile taa endovascular graft indicated for the treatment of patients with aneurysms/ulcers of the descending thoracic aorta having vessel structure suitable for repair.


Eligibility criteria:
inclusion criteria: * descending thoracic aneurysm with diameter ≥ 5.0 cm * descending thoracic aneurysm with a history of growth ≥ 0.5 cm per year * descending thoracic degenerative or atherosclerotic ulcer ≥ 10 mm in depth and 20 mm in diameter exclusion criteria: * less than 18 years of age * life expectancy less than 2 years * pregnant or breastfeeding or planning on becoming pregnant within 60 months * unwilling to comply with the follow-up schedule * inability or refusal to give informed consent * less than 30 days beyond primary endpoint for other investigative drug or device study

Keywords: aortic aneurysm aneurysm vascular prosthesis vascular disease blood vessel prosthesis implantation
haploidentical hematopoietic stem cell transplantation (hsct) for patients with severe sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to develop a safe and curative stem cell transplant approach to treating sickle cell disease by assessing the safety of haploidentical hematopoietic stem cell transplantation using αβ+ t-cell depletion for children and adolescents with severe sickle cell disease (scd).


Eligibility criteria:
inclusion criteria: * hemoglobin ss, sc, s-β0 thalassemia, or so-arab sickle cell disease * between the ages of 2 and 25 years (stage 1: 10-25 years; stage ii: 2-25 years) * lack a fully matched family donor or fully matched unrelated donor register in the national marrow donor program * partially-matched family member with hemoglobin aa (normal) or hemoglobin as (sickle trait) phenotype * scd with severe phenotype, defined by the following criteria: neurologic manifestations of sickle disease including cerebral vascular accident (cva), transient ischemic event (tia) or abnormal mri findings suggestive of silent infarct; two or more episodes of acute chest syndrome (acs) requiring admission for transfusional or respiratory support including supplemental oxygen within \[two years\] of enrollment in study despite hydroxyurea therapy. patients who cannot tolerate hydroxyurea and who experience multiple episodes of acs will also be eligible; history of severe vaso-occlusive (voc) disease requiring hospitalization and intravenous narcotics on 3 or more occasions per year over the two years prior to enrollment despite hydroxyurea therapy. patients who cannot tolerate hydroxyurea and who experience multiple episodes of voc will also be eligible; other severe phenotype as evidenced by end organ dysfunction related to sickle cell disease. exclusion criteria: * karnofsky or lansky score \< 60% * acute hepatitis or evidence of moderate or severe portal fibrosis on biopsy. (biopsy will be obtained if patient has been on chronic transfusion therapy \> 6 months or has a ferritin \> 1000 ng/ml) or ast or alt \>5 times the upper limit of normal * severe renal impairment (as evidenced by creatinine clearance of \<50ml/minute glomerular filtration rate (gfr) \< 50% predicted normal) * cardiac function that demonstrates shortening fraction less than 26% by cardiac echocardiogram or pulmonary hypertension. * pregnant female. * lactating female. * pulmonary function with baseline o2 saturation \<85% or diffusing capacity for carbon monoxide (dlco) on pulmonary function testing (pft) with a dlco \<40%.
suture of the ovary after enucleation of ovarian endometrioma

Conditions: Endometrioma

Summary: endometriosis is an estrogen-dependent chronic disease, characterized by the presence of ectopic endometrial-like tissue outside the uterine cavity. according to the most updated guidelines of the european society of human reproduction and embryology (eshre), infertile women with endometriomas smaller than 3 cm should be addressed directly to assisted reproduction technology (art); conversely, for infertile women with endometriomas larger than 3 cm, enucleation of ovarian endometriomas could be considered in order to improve reproductive outcomes (both spontaneous and art pregnancy rate). to date, literature data do not allow to draw a firm conclusion about the best strategy to reduce ovarian damage during enucleation of ovarian endometriomas: in particular, investigators still lack robust evidence in order to choose between suturing the ovary or not after the enucleation. in this scenario, the aim of our the study will be to compare functional outcomes of the ovary in a group of women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas (cases) and a group of women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.


Eligibility criteria:
inclusion criteria: * women affected by one primary (no recurrent) monolateral ovarian endometrioma, with maximum diameter between 5 and 10 cm, undergoing laparoscopic enucleation by stripping technique; * normal afc at the enrollment (baseline). exclusion criteria: * any other disease; * bilateral endometriomas; * deep infiltrating endometriosis; * no previous pelvic surgery (even not gynecological); * any other pharmacologic and non pharmacologic treatment in the previous 3 months (wash-out period);

Keywords: endometrioma laparoscopy suture ovary
utility of lung clearance index score as a noninvasive marker of small airways disease

Conditions: Chronic Lung Disease

Summary: to determine the utility and sensitivity of the lung clearance index (lci) technique as a marker of small airways disease in adults with chronic lung conditions compared to healthy adults, adjusting for age, sex and smoking status.

target population and enrollment. the study will recruit and consent 300 patients from our occupational medicine and interstitial lung/rheumatology clinics at national jewish health who have been referred for evaluation of chronic lung conditions. the healthy control group will comprise 300 volunteers who are at least 18 years of age, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment. inclusion criteria for the group with chronic lung disease will include physician diagnosis of a chronic lung condition (e.g. bronchiolitis, pulmonary fibrosis, asthma, coal mine dust lung disease, asbestosis), and age ≥18 years. exclusion criteria will include recent myocardial infarction, stroke, eye surgery, chest/abdominal surgery (within past month), known thoracic, aortic, or cerebral aneurysm, or uncontrolled hypertension. study participation will consist of one visit that will last between 90-120 minutes. the chronic lung disease group will fill out the informed consent and complete both lci testing and spirometry. the healthy control group will complete informed consent, a brief questionnaire, lci testing, and spirometry.

Eligibility criteria:
inclusion criteria: * physician diagnosis of a chronic lung condition (e.g. bronchiolitis, pulmonary fibrosis, asthma, coal mine dust lung disease, asbestosis), and age ≥18 years. the healthy control group will comprise 300 volunteers who are at least 18 years of age, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment exclusion criteria: * exclusion criteria will include recent myocardial infarction, stroke, eye surgery, chest/abdominal surgery (within past month), known thoracic, aortic, or cerebral aneurysm, or uncontrolled hypertension.
study evaluating metabolic syndrome in subjects undergoing gastric bypass bariatric syndrome

Conditions: Morbid Obesity; Metabolic Disease

Summary: metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving. patients with this syndrome are at increased risk for cardiovascular disease, and at increased risk of mortality from cardiovascular disease. metabolic syndrome is strongly associated with obesity, and more specifically with abdominal obesity. abdominal obesity, comprises two main components: visceral (vat) and subcutaneous (sat) adipose tissue depots, with vat reported as more metabolically active than sat, and thought to play a major role in the metabolic disturbances associated with obesity and metabolic syndrome. non-alcoholic fatty liver disease (nafld) is fast becoming the most common liver disease and is associated with obesity, insulin resistance and metabolic syndrome. bariatric surgery has yielded dramatic results including longitudinal loss of excess body weight and either complete reversal or significant improvement of several features of metabolic syndrome, nafld, and nonalcoholic steatohepatitis (nash) in obese patients.


Eligibility criteria:
inclusion criteria: * all subjects must be approved by both insurance and site standard of care to undergo the roux-en-y gastric bypass procedure * male and female candidates for roux-en-y bariatric surgery * must be diagnosed with metabolic syndrome; having abdominal obesity and at least 2 other features of the syndrome per idf (international diabetes foundation) * obese control group:subjects should be obese and should not have any other features of metabolic syndrome. exclusion criteria: * any subjects with prior bariatric surgery * no other major surgery within the last 6 months * diabetes on treatment with hypoglycemic medication in the previous 6 months other exclusions apply

Keywords: metabolic syndrome obesity nonalcoholic fatty liver disease nonalcoholic steatohepatitis bariatric surgery
pulmonary tele-rehabilitation and progressive muscle relaxation on discharged covid-19 patients

Conditions: Covid19

Summary: the aim of this study is to investigate efficacy of internet based pulmonary rehabilitation and progressive muscle relaxation program on functional capacity, depression and anxiety, dyspnea, fatigue, sleep quality and quality of life in covid19 patients after hospital discharge

novel coronavirus disease 2019 (covid19) could cause respiratory and physical dysfunction, anxiety and depression, fatigue and affect sleep quality and quality of life in infected patient after hospital discharge. there is expect that pulmonary rehabilitation can improve these symptoms and prevent complications in these cases. it seems that progressive muscle relaxation exercise could improve pulmonary rehabilitation effect. due to social isolation of covid 19 patients after hospital discharge, internet base rehabilitation will be used in this study. participants will be randomized in two pulmonary tele-rehabilitation groups after hospital discharge. one group will be received pulmonary rehabilitation include education, breathing exercises, aerobic and upper and lower limbs muscle strengthening exercises. another group will be perform progressive muscle relaxation in addition of these exercise. treatment duration is 6 week with 5 days/week frequency. two exercise sessions per week will be supervised with expert physiotherapist via videoconferencing. outcomes will be measured at baseline, within two week and at the end of six week exercises program.

Eligibility criteria:
inclusion criteria: * covid 19 patient that confirmed with polymerase chain reaction test (pcr) * hospitalized corvid 19 patients after discharge * accessibility to internet and using video call exclusion criteria: * mental and physical disability * uncontrolled cardiac dysfunction such as arrhythmia * sever neurological condition such as guillain-barre and stroke * uncontrolled diabetes or blood pressure * pregnant women * re-hospitalization during treatment program * chronic pulmonary and kidney condition
promoting maintenance of change following brief intervention for alcohol use

Conditions: Alcohol Drinking in College

Summary: all students who enroll in the study will receive an efficacious counselor-delivered brief motivational intervention. the intervention is based in principles of motivational interviewing. students complete a baseline assessment on their alcohol use and alcohol-related consequences. during the hour-long session, the counselor uses information from the baseline assessment to compare the student's level of alcohol consumption to that of peers at the same university, discuss choices that may lead to experiencing negative consequences, and provide opportunities for the student to set goals for risk reduction. this study will develop and pilot a maintenance enhancement intervention. the intervention is expected to consist of four components, for example: (1) student participants may learn to use techniques based in mindfulness to cope with negative emotions. (2) student participants may identify barriers to reducing their alcohol use and identify protective strategies for navigating those barriers. (3) student participants may be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. students may also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode. (4) parents may also receive a handbook encouraging communication with their student about alcohol use.


Eligibility criteria:
inclusion criteria: student participants must meet the following eligibility criteria: * currently enrolled student at the university of massachusetts amherst * first time violator of the university alcohol policy * mandated to complete the brief alcohol screening and intervention of college students (basics) intervention * minimum age 18 parent participants must meet the following eligibility criteria: • the parent or guardian of students who meet all of the student participant criteria exclusion criteria: • none.
patellar resurfacing in total knee arthroplasty

Conditions: Osteoarthritis; Pain

Summary: background: the best treatment of the patella during total knee arthroplasty (tka) is controversial. the implantation of a patellar component adds to the operation time and the costs of the operation.there is a huge variation as to whether the patella is resurfaced or not during tka. meta-analysis of prospective, randomised trials might indicate that patellar resurfacing reduces the risk of reoperation and anterior knee pain, but drawing firm conclusions is not possible and additional, high quality randomised trials are required. purpose: the aim of this study is to determine whether ther is a difference between the two groups in knee pain, functions, patient satisfaction and quality of life after tka.


Eligibility criteria:
inclusion criteria: * patients less than 85 years old with osteoarthritis scheduled for primary knee arthroplasty. exclusion criteria: * patients who are not able to cooperate * serious deformity (not suitable for a standard cr prosthesis) * patellar thickness less than 18 mm * prior operation involving the extensor mechanism * rheumatoid arthritis * severe medical disability limiting the ability to walk * revision surgery * knees with predominantly patellofemoral arthrosis

Keywords: replacement knee patella arthroplasty
value of advanced mri techniques in the assessment of endometriosis

Conditions: Endometriosis

Summary: endometriosis is a common gynaecological disease, mostly in women of reproductive age, with a prevalence of about 10 %, which is defined by the presence of endometrial-type tissue outside the uterine cavity. endometriosis is usually limited to the abdominal and especially the pelvic cavity, extra-abdominal lesions are rare. within the pelvis it shows a wide variety of locations predominantly affecting the ovaries and the uterus or the peritoneum, uterine ligaments and other pelvic structures. traditionally, there are three major phenotypes of endometriosis: ovarian endometrioma (oma), superficial peritoneal endometriosis (spe), and deep infiltrating endometriosis (die). a lesion is considered a die, if it shows infiltration deeper than 5 mm into the peritoneum. the ectopic endometrial implants may induce inflammatory processes, causing scar tissue formation, adhesions, and consequently pelvic anatomy distortion. the prospective study aims to investigate the value of advanced mri techniques to improve the assessment of pelvic endometriosis.


Eligibility criteria:
inclusion criteria: * patients who undergo clinically indicated mr imaging for endometriosis evaluation. exclusion criteria: * non-mri compatible devices/implants
breast mri as a preoperative tool for dcis

Conditions: Breast Cancer; Ductal Carcinoma in Situ

Summary: breast mri is a fairly new technology, but it has been well studied. it is now used routinely in many patients with breast cancer. it has been shown to be useful in detecting areas of cancer that cannot be seen using other types of scans or tests. the purpose of this study is to see how often mri can find other areas of cancer in women with one area of breast cancer, and to determine how having the mri test affects their treatment. the purpose is also to study any areas of abnormality seen on your mri with special methods that allow the images of your breast tissue and the microscopic analysis of your breast tissue to be compared very carefully. the study also aims to follow women who enter the study over a 10-year period to determine how often the breast cancer comes back.


Eligibility criteria:
inclusion criteria: * age less than 60 at time of consent * clinical stage is consistent with stage 0 or stage i t1mic at presentation * core biopsy proven dcis or dcis with microinvasion (invasion ≤0.1 cm), prior to enrollment * breast surgery to be performed at mskcc * informed consent obtained * female exclusion criteria: * age 60 or over at time of consent * patients who are pregnant or nursing * patients with contraindications to breast conservation * excisional biopsy of dcis or dcis with microinvasion, prior to enrollment * patients with any contraindications to mri including pacemaker, tissue expander, other metallic surgical implants, weight over 350 lb., previous gadolinium reaction, metal fragments in eye

Keywords: mri
low salt diet in idiopathic hypercalciuria

Conditions: Hypercalciuria

Summary: randomized clinical trial comparing water therapy plus low-salt diet to water therapy alone in patients affected by idiopathic calcium nephrolithiasis. treatment duration: three months primary end-point: correction of hypercalciuria main inclusion criteria: calcium stone formers with idiopathic hypercalciuria, with at least one stone expelled and analyzed by infrared spectrophotometry; presence of hypercalciuria (\>300 mg/day in males and \>200 mg/day in females); 18-65 years. main exclusion criteria: primary hyperparathyroidism, primary hyperoxaluria, enteric hyperoxaluria, bowel resection, inflammatory bowel disease, renal tubular acidosis, sarcoidosis, sponge kidney, hyperthyroidism, use of hypercalciuric drugs such as vitamin d, acetazolamide, anti-epileptic drugs


Eligibility criteria:
main inclusion criteria: * idiopathic calcium stone formers, with at least one stone expelled and analyzed by infrared spectrophotometry; presence of hypercalciuria (\>300 mg/day in males and 20 mg/day in females); * 18-65 years. main exclusion criteria: * primary hyperparathyroidism, * primary hyperoxaluria, * enteric hyperoxaluria, * bowel resection, * inflammatory bowel disease, * renal tubular acidosis, * sarcoidosis, sponge kidney, * hyperthyroidism, * use of hypercalciuric drugs such as vitamin d, * acetazolamide, * anti-epileptic drugs

Keywords: low salt diet, idiopathic hypercalciuria, calcium stone formers calcium stone formers with idiopathic hypercalciuria